Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.05 (1.45%)
Market Cap$128,131,500
Shares Outstanding36,609,000
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
10/20/14Cytokinetics Provides Development Program Update for TirasemtivPrinter Friendly Version
10/16/14Cytokinetics to Announce Third Quarter Results on October 30, 2014Printer Friendly Version
10/13/14Cytokinetics Announces Development Program Update for CK-2127107Printer Friendly Version
08/07/14Cytokinetics to Present at the 34th Annual Canaccord Global Growth ConferencePrinter Friendly Version
Upcoming EventsDetails >>
10/30/14 4:30 p.m. ET
Q3 2014 Cytokinetics, Inc. Earnings Conference Call
Featured ReportDetails >>
Download Documentation 2010 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.